Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2017

08.11.2016 | Epidemiology

Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors

verfasst von: Gregory S. Calip, Joann G. Elmore, Denise M. Boudreau

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

Comorbidity among breast cancer survivors is prevalent, and adherence to medication management of comorbidities may be important for both chronic disease and cancer-related outcomes. Our objective was to determine characteristics associated with nonadherence to common chronic medications among breast cancer survivors.

Methods

We conducted a retrospective cohort study of 4216 women in an integrated care system diagnosed with early-stage breast cancer between 1990 and 2008 and alive without recurrence or second primary breast cancer in the second-year following diagnosis. Adherence to antihypertensives, oral diabetes medications, and statins was measured during the second-year post-breast cancer diagnosis using medication possession ratios (MPR). Nonadherence was defined as MPR <0.80. We estimated odds ratios (OR) and 95% confidence intervals (CI) for nonadherence to antihypertensives, oral diabetes medications, and statins by various characteristics using multivariable logistic regression.

Results

Among 2308 users of antihypertensives (n = 1779), diabetes medications (n = 499) and/or statins (n = 1072), 37% were nonadherent to antihypertensives; 75% were nonadherent to diabetes medications; 39% were nonadherent to statins. In adjusted models, younger age was associated with nonadherence to all three therapeutic classes. Certain cancer treatments were associated with nonadherence to antihypertensives (radiation: OR 1.21, 95% CI 1.01–1.47; endocrine therapy: OR 1.27, 95% CI 1.03–1.52) and diabetes medications (chemotherapy: OR 1.69, 95% CI 1.17–2.21). Less frequent primary care provider visits were associated with higher odds of nonadherence to antihypertensives (OR 1.70, 95% CI 1.19–2.22); and trends showed higher Charlson comorbidity scores associated with greater adherence to diabetes medications (P < 0.001) and statins (P = 0.032).

Conclusions

Nonadherence to medications is high among breast cancer survivors, particularly diabetes medications, and is associated with cancer treatments and other patient characteristics. Additional research is warranted to understand the needs of cancer patients taking chronic medications and explore patient and provider factors influencing adherence.
Literatur
2.
4.
Zurück zum Zitat Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461–1468. doi:10.1093/jnci/djr291 CrossRefPubMedPubMedCentral Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461–1468. doi:10.​1093/​jnci/​djr291 CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573–579. doi:10.1007/s10549-007-9683-8 CrossRefPubMed Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573–579. doi:10.​1007/​s10549-007-9683-8 CrossRefPubMed
8.
Zurück zum Zitat Steiner JF, Ho PM, Beaty BL, Dickinson LM, Hanratty R, Zeng C, Tavel HM, Havranek EP, Davidson AJ, Magid DJ, Estacio RO (2009) Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2(5):451–457. doi:10.1161/CIRCOUTCOMES.108.841635 CrossRefPubMedPubMedCentral Steiner JF, Ho PM, Beaty BL, Dickinson LM, Hanratty R, Zeng C, Tavel HM, Havranek EP, Davidson AJ, Magid DJ, Estacio RO (2009) Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2(5):451–457. doi:10.​1161/​CIRCOUTCOMES.​108.​841635 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Peyrot M, McMurry JF Jr, Kruger DF (1999) A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav 40(2):141–158CrossRefPubMed Peyrot M, McMurry JF Jr, Kruger DF (1999) A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav 40(2):141–158CrossRefPubMed
12.
Zurück zum Zitat Zanders MM, Haak HR, van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA (2015) Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia 58(5):951–960. doi:10.1007/s00125-015-3497-8 CrossRefPubMed Zanders MM, Haak HR, van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA (2015) Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia 58(5):951–960. doi:10.​1007/​s00125-015-3497-8 CrossRefPubMed
14.
Zurück zum Zitat Higashi T, Wenger NS, Adams JL, Fung C, Roland M, McGlynn EA, Reeves D, Asch SM, Kerr EA, Shekelle PG (2007) Relationship between number of medical conditions and quality of care. N Engl J Med 356(24):2496–2504. doi:10.1056/NEJMsa066253 CrossRefPubMed Higashi T, Wenger NS, Adams JL, Fung C, Roland M, McGlynn EA, Reeves D, Asch SM, Kerr EA, Shekelle PG (2007) Relationship between number of medical conditions and quality of care. N Engl J Med 356(24):2496–2504. doi:10.​1056/​NEJMsa066253 CrossRefPubMed
15.
Zurück zum Zitat Min LC, Wenger NS, Fung C, Chang JT, Ganz DA, Higashi T, Kamberg CJ, MacLean CH, Roth CP, Solomon DH, Young RT, Reuben DB (2007) Multimorbidity is associated with better quality of care among vulnerable elders. Med Care 45(6):480–488. doi:10.1097/MLR.0b013e318030fff9 CrossRefPubMed Min LC, Wenger NS, Fung C, Chang JT, Ganz DA, Higashi T, Kamberg CJ, MacLean CH, Roth CP, Solomon DH, Young RT, Reuben DB (2007) Multimorbidity is associated with better quality of care among vulnerable elders. Med Care 45(6):480–488. doi:10.​1097/​MLR.​0b013e318030fff9​ CrossRefPubMed
16.
Zurück zum Zitat American Cancer Society (2013) Breast cancer facts & figures 2013–2014. American Cancer Society Inc., Atlanta American Cancer Society (2013) Breast cancer facts & figures 2013–2014. American Cancer Society Inc., Atlanta
17.
Zurück zum Zitat Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM (2015) Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24(1):75–85. doi:10.1002/pds.3660 CrossRefPubMed Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM (2015) Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24(1):75–85. doi:10.​1002/​pds.​3660 CrossRefPubMed
19.
Zurück zum Zitat Santorelli ML, Steinberg MB, Hirshfield KM, Rhoads GG, Bandera EV, Lin Y, Demissie K (2016) Effects of breast cancer on chronic disease medication adherence among older women. Pharmacoepidemiol Drug Saf 25(8):898–907. doi:10.1002/pds.3971 CrossRefPubMed Santorelli ML, Steinberg MB, Hirshfield KM, Rhoads GG, Bandera EV, Lin Y, Demissie K (2016) Effects of breast cancer on chronic disease medication adherence among older women. Pharmacoepidemiol Drug Saf 25(8):898–907. doi:10.​1002/​pds.​3971 CrossRefPubMed
20.
21.
23.
Zurück zum Zitat Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223–239 Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223–239
25.
Zurück zum Zitat Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–574. doi:10.1002/pds.1230 CrossRefPubMed Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–574. doi:10.​1002/​pds.​1230 CrossRefPubMed
27.
Zurück zum Zitat Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, Solomon DH (2009) Measuring concurrent adherence to multiple related medications. Am J Manag Care 15(7):457–464PubMedPubMedCentral Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, Solomon DH (2009) Measuring concurrent adherence to multiple related medications. Am J Manag Care 15(7):457–464PubMedPubMedCentral
28.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRefPubMed
30.
Zurück zum Zitat Lau DT, Nau DP (2004) Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 27(9):2149–2153CrossRefPubMed Lau DT, Nau DP (2004) Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 27(9):2149–2153CrossRefPubMed
31.
Zurück zum Zitat Hepke KL, Martus MT, Share DA (2004) Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 10(2 Pt 2):144–151PubMed Hepke KL, Martus MT, Share DA (2004) Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 10(2 Pt 2):144–151PubMed
32.
33.
Zurück zum Zitat Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, Shetterly S, Xu S, Steiner JF (2012) Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 27(1):57–64. doi:10.1007/s11606-011-1829-z CrossRefPubMed Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, Shetterly S, Xu S, Steiner JF (2012) Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 27(1):57–64. doi:10.​1007/​s11606-011-1829-z CrossRefPubMed
34.
Zurück zum Zitat Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J (1996) Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 86(12):1805–1808CrossRefPubMedPubMedCentral Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J (1996) Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 86(12):1805–1808CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Janz NK, Becker MH (1984) The Health Belief Model: a decade later. Health Educ Q 11(1):1–47CrossRefPubMed Janz NK, Becker MH (1984) The Health Belief Model: a decade later. Health Educ Q 11(1):1–47CrossRefPubMed
36.
Zurück zum Zitat Olson KL, Rasmussen J, Sandhoff BG, Merenich JA, Clinical Pharmacy Cardiac Risk Service Study G (2005) Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med 165(1):49–54. doi:10.1001/archinte.165.1.49 CrossRefPubMed Olson KL, Rasmussen J, Sandhoff BG, Merenich JA, Clinical Pharmacy Cardiac Risk Service Study G (2005) Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med 165(1):49–54. doi:10.​1001/​archinte.​165.​1.​49 CrossRefPubMed
37.
Zurück zum Zitat McCulloch DK, Price MJ, Hindmarsh M, Wagner EH (1998) A population-based approach to diabetes management in a primary care setting: early results and lessons learned. Eff Clin Pract 1(1):12–22PubMed McCulloch DK, Price MJ, Hindmarsh M, Wagner EH (1998) A population-based approach to diabetes management in a primary care setting: early results and lessons learned. Eff Clin Pract 1(1):12–22PubMed
38.
Zurück zum Zitat Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, Wolff AC (2009) Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 24(Suppl 2):S459–S466. doi:10.1007/s11606-009-1000-2 CrossRefPubMed Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, Wolff AC (2009) Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 24(Suppl 2):S459–S466. doi:10.​1007/​s11606-009-1000-2 CrossRefPubMed
40.
Zurück zum Zitat Hewitt ME, Ganz PA, Institute of Medicine (U.S.), American Society of Clinical Oncology (U.S.) (2006) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington Hewitt ME, Ganz PA, Institute of Medicine (U.S.), American Society of Clinical Oncology (U.S.) (2006) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington
43.
Zurück zum Zitat Mozumdar A, Liguori G (2011) Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care 34(1):216–219. doi:10.2337/dc10-0879 CrossRefPubMed Mozumdar A, Liguori G (2011) Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care 34(1):216–219. doi:10.​2337/​dc10-0879 CrossRefPubMed
44.
46.
Zurück zum Zitat Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238. doi:10.1002/ijc.21812 CrossRefPubMed Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238. doi:10.​1002/​ijc.​21812 CrossRefPubMed
47.
Zurück zum Zitat Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, Mercandino A, Galasso R, Barbero M, Simeoni M, Bassi MC, Consolaro E, Johansson H, Zarcone M, Bruno E, Gargano G, Venturelli E, Pasanisi P (2014) Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat 147(1):159–165. doi:10.1007/s10549-014-3076-6 CrossRefPubMed Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, Mercandino A, Galasso R, Barbero M, Simeoni M, Bassi MC, Consolaro E, Johansson H, Zarcone M, Bruno E, Gargano G, Venturelli E, Pasanisi P (2014) Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat 147(1):159–165. doi:10.​1007/​s10549-014-3076-6 CrossRefPubMed
48.
Zurück zum Zitat Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT, Whelton PK Jr, Group SSR (2014) The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11(5):532–546. doi:10.1177/1740774514537404 CrossRefPubMed Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT, Whelton PK Jr, Group SSR (2014) The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11(5):532–546. doi:10.​1177/​1740774514537404​ CrossRefPubMed
49.
Zurück zum Zitat American Diabetes Association (2015) Standards of medical care in diabetes–2015. Diabetes Care 38(Suppl 1):S1–S98. doi:10.2337/dc15-S001 American Diabetes Association (2015) Standards of medical care in diabetes–2015. Diabetes Care 38(Suppl 1):S1–S98. doi:10.​2337/​dc15-S001
50.
Zurück zum Zitat James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520. doi:10.1001/jama.2013.284427 CrossRefPubMed James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520. doi:10.​1001/​jama.​2013.​284427 CrossRefPubMed
51.
Zurück zum Zitat Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(25 Pt B):2889–2934. doi:10.1016/j.jacc.2013.11.002 CrossRefPubMed Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(25 Pt B):2889–2934. doi:10.​1016/​j.​jacc.​2013.​11.​002 CrossRefPubMed
52.
Zurück zum Zitat Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7–8):1317–1318. doi:10.1345/aph.1D569 CrossRefPubMed Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7–8):1317–1318. doi:10.​1345/​aph.​1D569 CrossRefPubMed
Metadaten
Titel
Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors
verfasst von
Gregory S. Calip
Joann G. Elmore
Denise M. Boudreau
Publikationsdatum
08.11.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4043-1

Weitere Artikel der Ausgabe 1/2017

Breast Cancer Research and Treatment 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.